Chiang LingLi

Partner

(T) 852.3189.7338

Chiang Ling Li's practice has focused on China IP and pharmaceutical law since 1994. She has been in the forefront of the law, leading successful litigation involving patents, trade secrets, copyright, unfair competition, 3-D marks and well-known marks, as well as successfully pursuing criminal enforcement of IP infringement in China.

Chiang works closely with industry organizations lobbying for legal reforms, including those concerning patent linkage and data exclusivity, and has been appointed an arbitrator by CIETAC, HKIAC, ADNDRC, and the WIPO Arbitration and Mediation Center.

Chiang is author of China Executive Report: Intellectual Property, the China IP chapters of LexisNexis's Intellectual Property Rights, the "Anticounterfeiting and Enforcement" chapter in China's Participation in the WTO, and the China chapters in PLC Cross-border Life Sciences (2007-2012 editions), Trade Secrets Throughout the World Treatise, Patents Throughout the World, and Designs and Utility Models Throughout the World. She is also author of many articles on China IP and pharmaceutical law and practice.

Chiang was among the "A-List" of the top 100 lawyers for China (China Business Law Journal). She is also a PLC recommended lawyer in all three categories of life sciences: intellectual property, corporate and commercial (China), and corporate and commercial. Chiang also has been recognized by The International Who's Who of Life Sciences Lawyers, World Trademark Review (WTR 1000), Chambers Asia and Chambers Global, The International Who's Who of Life Sciences Lawyers, The International Who's Who of Business Lawyers, IAM 1000 — The World's Leading Patent Professionals, WTR 1000 — The World's Leading Trademark Professionals, and IAM Licensing 250: The World's Leading Patent and Technology Licensing Practitioners.

Experience

  • Arsenal Capital Partners acquires HistoGeneX and Caprion BiosciencesJones Day advised Arsenal Capital Partners on major investments in HistoGeneX and Caprion Biosciences and the subsequent combination of the two businesses.
  • Incyte grants license to and collaborates with Zai Lab to develop and commercialize anti-PD1 pharmaceutical products in ChinaJones Day represented Incyte Corporation in its sublicense out to Zai Lab Limited of certain intellectual property rights to an anti-PD1 molecule licensed to Incyte from MacroGenics, Inc. globally in 2017 and which Incyte is actively developing in the U.S. and other jurisdictions outside of China.
  • Wipro to acquire Splash CorporationJones Day is advising Wipro Enterprises Private Ltd. (Wipro) in its acquisition of Splash Corporation, a leading personal care products player in the Philippines, from Ang Hortaleza Corporation.
  • Incyte enters strategic collaboration agreement with Innovent for three clinical pharmaceuticals in ChinaJones Day represented Incyte Pharmaceuticals in its strategic collaboration and license agreement with Innovent Biologics for the regulatory development and commercialization in China of three clinical stage pharmaceutical candidates, a FGFR1/2/3 inhibitor, a JAK1 inhibitor, and a PI3K delta inhibitor, for treatment of hematological and oncological diseases.
  • ANSYS acquires OPTISJones Day advised ANSYS, Inc., the global leader and innovator of engineering simulation software, on its acquisition of OPTIS, a premier provider of software for scientific simulation of light, human vision, and physics-based visualization.
  • AGIC Capital acquires Fotona from The Gores GroupJones Day advised Asia-Germany Industrial Promotion Limited ("AGIC Capital"), an Asian-European private equity investor focused on industrial technology companies in the European and North American mid-market, in connection with the acquisition and related financing of Fotona, a U.S. and Slovenia based developer of high-tech laser systems and components, primarily used in medicine, aesthetics, surgery, gynecology, and dentistry, from private equity firm, The Gores Group.
  • Cardinal Health acquires leading patient product portfolio from Medtronic for $6.1 billionJones Day advised Cardinal Health on the acquisition of Medtronic's Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion in cash.
  • Shore Capital Partners portfolio company acquires vertebroplasty family of products from Cook MedicalJones Day represented Shore Capital Partners in connection with the acquisition by portfolio company IZI Medical Products, LLC, a manufacturer of medical consumable accessories used in radiology, radiation therapy, and image guided surgery procedures, of the vertebroplasty family of products from Cook Medical, a family-owned medical device company.
  • Japanese trading company creates ground-breaking cross-border e-commerce platformJones Day advised Itochu Corporation, the major trading company in Japan, and its affiliate in the establishment of a ground-breaking, cross-border e-commerce platform with one of China’s largest state-owned enterprises, CITIC Holdings Co. Ltd. and its affiliate.
  • U.S. biotechnology company reviews lab management consulting contract in ChinaJones Day advised a U.S. biotechnology company in relation to the lab management consulting contract reviews in China.
  • International medical device manufacturer protects against parallel imports in ChinaJones Day advised an international medical device manufacturer on strategizing its protection program for its medical devices in China against parallel imports from countries such as Australia, Singapore, and the United States.
  • International medical device company seeks trademark protection for its wound care products in ChinaJones Day advised an international medical device company on the protection of trademarks in China relating to technology in wound dressing products to stop bleeding, promote wound closure, and aid in wound healing.
  • Biopharmaceutical company seeks trademark protection for antibodies for pharmaceutical preparations in ChinaJones Day advised a biopharmaceutical company on the protection of trademark relating to the marker phosphatidylserine (PS) and antibodies for the treatment and diagnosis of cancer, infectious diseases, and diseases and disorders.
  • Medical grade garments manufacturer licenses its medical devices in AsiaJones Day advised a manufacturer of medical grade and fully-customizable compression garments on its IP and market authorization structuring for its medical devices in China and in Asia.
  • Medical equipment manufacturer receives antitrust trainingJones Day advised and provided training for officers and employees of a medical equipment manufacturer in regards to antitrust dawn raids.
  • XIO acquires Lumenis for approximately $510 million, $14 per share, in cashJones Day advised XIO Group in its acquisition of Lumenis Ltd., the world's largest energy-based medical company for surgical, ophthalmology, and aesthetic applications, for $14 per share in cash, for an aggregate purchase price of approximately $510 million.
  • Cardinal Health acquires Cordis for $1.9 billionJones Day advised Cardinal Health, Inc. in its acquisition of Johnson & Johnson's Cordis business, a leading global manufacturer of cardiology and endovascular devices, for $1.9 billion in cash.
  • U.S. health system provider protects data privacy on its mobile health application in ChinaJones Day advised a U.S. health system provider on its review of IP issues in connection with its mobile health application which is integrated with medical devices that can monitor patient asthma symptoms and transmit that information to healthcare professionals.
  • Ikaria announces strategic partnership with Lee's Pharmaceutical for sale of Ikaria's INOMAX Total Care services packageJones Day advised INO Therapeutics LLC d/b/a Ikaria in a series of transactions with Lee's Pharmaceutical (Hong Kong) Limited for the promotion and sales of Ikaria's INOMAX Total Care services package (including device, drug, and accessories for neo-natal pulmonary therapy that treats infant hypoxic respiratory failures) in Greater China (including mainland China, Hong Kong/Macau and Taiwan).
  • Australian nonprofit non-governmental organization builds IP portfolio in ChinaJones Day advised an Australian nonprofit non-governmental organization on their intellectual property portfolio and transactions for eye care research, education, manufacturing, sales, and distribution in China.
  • Additional Publications

    • 2011Designs and Utility Models Throughout the World, China Executive Report: Intellectual Property
    • 2011Patents Throughout the World, China Executive Report: Intellectual Property
    • 2011PLC Cross-border Life Sciences 2007/08, China Executive Report: Intellectual Property
    • 2011Trade Secrets Throughout the World Treatise, China Executive Report: Intellectual Property
    • 2011Trademark, Copyright, Trade Secret and Patent, Pendleton, Margolis and Lee: Intellectual Property Rights Hong Kong SAR and People's Republic of China
    • 2009The Radical Third Amendment, 2009 China IP Focus, Managing Intellectual Property
    • 2005Anti-counterfeiting and Enforcement chapter, China's Participation in the WT
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.